FRIDAY, July 22, 2022 (HealthDay News) Long-term treatment of severe asthma with dupilumab supports sustained reduction in oral corticosteroid (OCS) dosage and improvement in clinical end points for up to 96 weeks, according to a study published in the July issue of CHEST. Lawrence D. Sher, M.D., from Peninsula Research Associates in Rolling Hills
OCS-Sparing Effect of Dupilumab for Severe Asthma Maintained vtcng.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vtcng.com Daily Mail and Mail on Sunday newspapers.
OCS-Sparing Effect of Dupilumab for Severe Asthma Maintained kxly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kxly.com Daily Mail and Mail on Sunday newspapers.